Phio Pharma gets FDA acceptance of PH-762 nonclinical study design; tox study Q1 2026

Phio Pharmaceuticals Corp.

FDA accepted nonclinical protocol study design for PH-762; toxicology study to begin Q1 2026.
Interim Phase 1b results: 6 complete responses among 16 evaluable cSCC patients; no dose-limiting toxicities.
Company advancing cGMP drug product delivery in 2026, partially funded by recent financing.
PH-762 well tolerated in all enrolled patients across five dose cohorts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.